ACI-35 / J&J, AC Immune - LARVOL DELTA

ANTIBODIES GENERATED BY JNJ-64042056, AN ACTIVE ANTI-PTAU IMMUNOTHERAPY, IN CLINICAL TRIAL ACI-35-1802 CAN BLOCK TAU SEEDING IN NEURONS. (ADPD 2025) - P2 | "Conclusions This work demonstrates that JNJ-64042056 induces an immune response in patients with AD that is capable of binding to AD-tau seeds and, therefore, has the potential to prevent tau aggregation induction and spreading in the human brain, which is the intended mode of action set for this anti-tau active immunotherapy. JNJ-64042056 is currently being tested in participants who have preclinical AD with confirmed tau pathology (ReTain Phase 2b trial, NCT06544616)."

Clinical • Alzheimer's Disease • CNS Disorders

[VIRTUAL] DEVELOPMENT OF ACI-35.030, A SECOND GENERATION ANTI-PHOSPHO TAU VACCINE, IN CLINICAL EVALUATION FOR THE TREATMENT OF ALZHEIMER’S DISEASE (AAT-ADPD 2020) - "Furthermore, the safety profile remained satisfactory. Conclusions ACI-35.030 builds on the success of the ACI-35 vaccine, and is currently being evaluated in a Phase 1b/2a in AD."

Clinical • Alzheimer's Disease • CNS Disorders • Tauopathies And Synucleinopathies

AC Immune reports Q2 2019 financial results, business and clinical update (GlobeNewswire) - "R&D expenditures increased by CHF 2.2 million (+21%) and CHF 3.7 million (+18%) for the three and six months ended June 30, 2019 compared to the comparable periods in 2018, respectively. The Company largely increased its investments in AD, non-AD and new discovery programs. For AD, the Company prepared activities for its Phase 1b/2a and Phase 2 studies for ACI-35 and ACI-24 AD, respectively."

Commercial

AC Immune reports full-year 2018 financial results and provides business update (GlobeNewswire) - "Alzheimer’s disease expenses increased due to a CHF 3.0 million increase for investments related to the completion of the Phase 1b study for ACI-35 and advancement of the vaccine through the development plan. ACI-24 AD spend increased by CHF 1.4 million in set-up fees such as site selection, administration and related manufacturing costs associated with the Phase 2 study."

Commercial

AC Immune reports full-year 2018 financial results and provides business update (GlobeNewswire) - "ACI-35 to start Phase 2 testing in H1 19."

New P2 trial

AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer’s Disease (GlobeNewswire, AC Immune SA) - "AC Immune SA...today announced that Genentech, a member of the Roche Group, is recruiting patients for a second Phase 2 trial for an anti-Tau monoclonal antibody, known as MTAU9937A, RO7105705, in moderate Alzheimer’s disease (AD). The same antibody, RG6100 (MTAU9937A, RO7105705), also is being studied by Genentech in a separate Phase 2 trial to evaluate its efficacy and safety in patients with prodromal-to-mild Alzheimer's disease...ACI-35...currently in a Phase 1b/2a trial, a small molecule Tau MorphomerTM, partnered with Eli Lilly and Company, that is scheduled to enter Phase 1 in 2019..."

Enrollment status • New P1 trial